Funder
SERB
Department of Biotechnology, Ministry of Science and Technology, India
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Cellular and Molecular Neuroscience,Pharmacology,Molecular Biology,Molecular Medicine
Reference63 articles.
1. Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer. Evolution of management in the era of precision medicine. CA Cancer J Clin 69:280–304. https://doi.org/10.3322/caac.21559
2. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708
3. Howlader N, Noone AM, Krapcho M, Miller D, Brest A Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, National Cancer Institute, Bethesda, MD (1975–2017). https://seer.cancer.gov/csr/1975_2017/ based on November 2019 SEER data submission, posted to the SEER web site, April 2020
4. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, DeGeest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419–1425. https://doi.org/10.1200/JCO.2008.19.1684
5. du Bois A, Lück H-J, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329. https://doi.org/10.1093/jnci/djg036
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献